Patent US4579844A successfully refreshed from Google Patents.
US4579844A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical anti-inflammatory drug therapy
Assignee: Johnson and Johnson
•
Filing: 1984-03-22
•
Granted: 1986-04-01
•
Expires: 2004-03-22
Abstract
Abstract A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolon derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.
Inventors
- 👤 David T. Rovee
- 👤 John R. Marvel
- 👤 James A. Mezick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 04:49
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/58; A61K31/60
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
173 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of arylacetohydroxamic acids of the formula ##STR1## wherein R and R' represent an alkyl C 1 -C 6 , cycloalkyl C 5 -C 6 , alkoxy C 1 -C 6 , alkenyloxy C 5 -C 6 , cycloalkenyloxy C 5 -C 6 , alkylthio C 1 -C 6 , cycloalkyloxy C 5 -C 6 , cycloalkylalkyloxy (with cycloalkyl C 5 -C 6 and alkyl C 1 -C 6 ), or arylalkyloxy C 1 -C 6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and, concurrent therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle, the amounts of said anti-inflammatory drugs being sufficient in combination to combat said inflammatory condition.
Claim 2
Independent Claim
173 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of arylacetohydroxamic acids of the formula ##STR1## wherein R and R' represent an alkyl C 1 -C 6 , cycloalkyl C 5 -C 6 , alkoxy C 1 -C 6 , alkenyloxy C 5 -C 6 , cycloalkenyloxy C 5 -C 6 , alkylthio C 1 -C 6 , cycloalkyloxy C 5 -C 6 , cycloalkylalkyloxy (with cycloalkyl C 5 -C 6 and alkyl C 1 -C 6 ), or arylalkyloxy C 1 -C 6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and, concurrent therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle, the amounts of said anti-inflammatory drugs being sufficient in combination to combat said inflammatory condition.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 5
Dependent Claim
37 words
The method of claim 2 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said topically active corticosteroid comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 6
Dependent Claim
22 words
A method of treating inflammatory conditions of the skin which comprises topically applying to the affected area the composition of claim 4.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein said substituted arylacetohydroxamic acid is bufexemac.
Claim 8
Dependent Claim
12 words
The method of claim 1 wherein said substituted arylacetohydroxamic acid is bufexemac.
Claim 9
Dependent Claim
159 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle containing a non-steroidal a inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of an acyl acetohydroxamic acid of the formula ##STR2## wherein R and R' represent alkyl C 1 -C 6 , cycloalkyl C 5 -C 6 , alkoxy C 1 -C 6 , alkenyloxy C 5 -C 6 , cycloalkenyloxy C 5 -C 6 , alkylthio C 1 -C 6 , cycloalkyloxy C 5 -C 6 , cycloalkylakyloxy C with cycloalkyl C 5 -C 6 and alkyl C 1 -C 6 , or arylalkyloxy C 1 -C 6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 10
Dependent Claim
159 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle containing a non-steroidal a inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of an acyl acetohydroxamic acid of the formula ##STR2## wherein R and R' represent alkyl C 1 -C 6 , cycloalkyl C 5 -C 6 , alkoxy C 1 -C 6 , alkenyloxy C 5 -C 6 , cycloalkenyloxy C 5 -C 6 , alkylthio C 1 -C 6 , cycloalkyloxy C 5 -C 6 , cycloalkylakyloxy C with cycloalkyl C 5 -C 6 and alkyl C 1 -C 6 , or arylalkyloxy C 1 -C 6 radical, R and R' can be the same or different, R' can also be hydrogen, and n has a value of 0 to 2, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 11
Dependent Claim
17 words
The composition of claim 8 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 12
Dependent Claim
17 words
The composition of claim 8 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 13
Dependent Claim
36 words
The composition of claim 9 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition further comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 14
Dependent Claim
15 words
The composition of claim 10 wherein said concentration is from about 0.05% to about 0.1%.
Claim 15
Dependent Claim
15 words
The composition of claim 10 wherein said concentration is from about 2% to about 5%.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-03-31 | 1989-09-30 | 1990-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-03-31 | 1993-09-30 | 1994-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-03-31 | 1997-09-30 | 1998-04-01 | $7700.00 | Window Closed / Lapsed |